Index Health Authority Therapy Title Trial # Phase For US Locations & Contacts Notes
1 FDA IPI-504 Safety Study of IPI-504 for GASTROINTESTINAL Stromal Tumors (GIST) NCT00276302 I GIST Dana Farber, Boston, MA - Michael T Quigley, RN,  617-632-5117, Michael_Quigley@dfci.harvard.edu; Univ. Of Mich., Ann Arbor, MI Rashmi Chugh, MD, 734-936-0453, rashmim@umich.edu   
2 Unspecified Genasense + Gleevec Oblimersen and Imatinib Mesylate in Treating Patients With Advanced GASTROINTESTINAL Stromal Tumors That Cannot Be Removed By Surgery NCT00091078 I GIST Dana Farber Cancer Institute, Boston, MA, 617-582-8480; University of Michigan Ann Arbor, MI, 800-865-1125; Mayo Clinic Cancer Center, Rochester, MN, 507-538-7623, cancerclinicaltrials@mayo.edu; Memorial Sloan-Kettering Cancer Center, New York, NY, Robert Maki, MD, PhD,  212-639-5720; M.D. Anderson Cancer Center, Houston,  TX,  713-792-3245  
3 MDACC Perifosine + Gleevec Phase II Study of Perifosine plus Imatinib Mesylate for Patients With Resistant Gastrointestinal Stromal Tumor (GIST) MDACC 2004-0968 II GIST M.D Anderson Cancer Center, Houston, TX, 800-392-1611; Oncology Specialists, Park
Ridge, IL; Cancer Center at Century City, Los Angeles, CA, Dr. Sant Chawla; Outside US 713-792-6161		  
4 FDA Perifosine + Sutent Perifosine + Sunitinib Malate for Patients With Advanced Cancers NCT00399152 I GIST/RCC Online Collaborative Oncology Group, 415-946-2410, ocogtrials@ocog.net; Huntsville, AL; Tower
Hematology and Oncology, Beverly Hills, CA, Pomona, CA; Santa Monica, CA; Kalamazoo, MI		 Check what happened to Park Ridge, IL
5 FDA BMS-354825 A Phase I Dose-Escalation Study of BMS-354825 in Patients With Refractory Solid Tumors NCT00099606 I Neoplasms BMS Call Center, 1-866-892-1BMS  Ext. 131; Dana Farber Boston, MA; Karmanos Cancer Center, Detroit, MI  
6 FDA Sorafenib Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate NCT00265798 II GIST University of Chicago Cancer Research Center, Chicago, IL, 773-834-7424 Check other sites Decatur, Peoria, MSKCC
7 FDA Flavopiridol + Doxorubicin Doxorubicin and Flavopiridol in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery NCT00098579 I GIST/Sarcoma Memorial Sloan-Kettering Cancer Center, New York, NY, David R. D'Adamo, MD, PhD, 212-639-7573  
8 Unspecified FR901228 FR901228 in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma NCT00112463 II GIST/Sarcoma/Ewings Wake Forest University Comprehensive Cancer Center, Winston-Salem,  NC, 336-713-6771, Paul D. Savage, MD,  Study Chair What about 15 other sites
9 Nevada Cancer Inst. LBH589 A Phase IA, two-arm, multi-center, dose escalating study of LBH589 administered intravenously on two dose schedules in adult patients with advanced solid tumors & non-Hodgkin’s lymphoma. NVCI I Advanced Solid Tumors Nevada Cancer Institute, Las Vegas, NV, Donna Adkins, (702) 822-5173  
10 FDA CNF2024 Study of Oral CNF2024 in Advanced Solid Tumors or Lymphomas NCT00345189 I Tumors/Lymphoma Biogen Idec, oncologyclinicaltrials@biogenidec.com; Scottsdale, AZ; New Haven, CT; San Antomio, TX  
11 FDA XL820 Study of XL820 Given Orally Daily to Subjects With Solid Tumors NCT00350831 I Cancer/Solid Tumor The Cancer Institute of New Jersey, New Brunswick,  NJ, Pamela Scott, 732-235-7459, scottpd@umdnj.edu, Mark Stein, MD, Principal Investigator; Cancer Therapy and Research Center, San Antonio, TX, Pat O'Rourke,  210-616-5976, porourke@idd.org, Kyriakos P. Papadopoulos, MD, Principal Investigator  
12   OSI-930 A Phase I Dose Escalation Study of Daily Oral OSI-930 in Patients with Advanced Solid Tumors   I Advanced Solid Tumors Dana Farber, Boston, MA - Michael T Quigley, RN,  617-632-5117, Michael_Quigley@dfci.harvard.edu; Colorado University, Denver, CO